Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Contract

13 Sep 2006 07:03

PuriCore Plc13 September 2006 PuriCore Announces Major Supermarket Contract Awarded to Sterilox Food Safety Division MALVERN, PENNSYLVANIA, and STAFFORD, UK, September 13, 2006 -- PuriCore plc("PuriCore") (London Stock Exchange: PURI), the developer of a novel, safetechnology that mimics the human body's natural anti-microbial, hypochlorousacid, announces today that its Sterilox Food Safety division has been awarded acontract from a major US supermarket chain, worth approximately $3.3 million incumulative revenue and cash flow over a three year period. This contract, whichis the second largest in PuriCore's history, represents an initial order forjust over 200 Sterilox Systems to be leased over a three year period.Installation of these Systems is expected to commence in September and to becompleted by the end of the year. With this new order, PuriCore anticipates it will have an installed base of over1,400 Sterilox Systems in US supermarkets by year end. The Sterilox System produces a food safe sanitizer from only water and commonsalt which, when converted through patented technology, provides retailers witha solution to potential cross contamination of harmful bacteria or spoilageorganisms in the produce, seafood and floral departments. The Sterilox System'sproprietary technology has been proven to substantially reduce shrink and labourcosts while improving the freshness and safety of retailers' products. TheSterilox System is fully automated and uses very little floor space, which isideal for supermarket backrooms. The sanitizer is non-toxic, food safe, FDAallowed and EPA registered. Tom Daniel, Senior Vice President of PuriCore's Sterilox Food Safety division,commented, "Over the past few years, Sterilox Food Safety has pioneered thismarket segment with numerous leading grocery retailers. Our leadershipposition, both in technology advancement and commercial know-how, is evidence ofthe value that we continue to deliver to our customers." Greg Bosch, CEO of PuriCore, added, "We have seen excellent growth in our FoodSafety division this year and this new contract confirms the potential for ourtechnology to maintain the freshness and safety of food. With trials underwayat a number of other major US supermarket chains, we are confident ofmaintaining our momentum in this sector." FOR FURTHER INFORMATION: PuriCore plc Tel: +1 (484) 321-2701Greg Bosch, Chief Executive OfficerKeith A. Goldan, Chief Financial Officer Financial Dynamics Tel: +44 (0) 20 7831 3113David YatesSarah MacLeodJohn Gilbert ABOUT PURICORE PLC PuriCore is a life sciences company focused on the development andcommercialization of its proprietary technology that mimics the production bythe human body of its natural anti-microbial, hypochlorous acid. Hypochlorousacid is highly effective at killing pathogens such as bacteria, viruses andfungi and yet is safe and environmentally friendly. PuriCore's solutions haveapplications in a wide range of markets where it is important to controlmicrobial contamination. These markets include medical device disinfection,food safety, dental equipment decontamination, environmental remediation,hospitality, water safety, wound management and other applications intended tolimit the spread of infectious disease, including major global disease threatssuch as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, HepatitisA, H.pylori and Legionella. PuriCore markets a portfolio of branded systems which produce hypochlorous acidsolutions on-site at a customer's location from water, electricity and commonsalt. These solutions are generated at a range of concentrations and at anearly neutral pH range similar to the human body. They are effective as soaks,sprays, mists and in other forms. PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,UK. To receive additional information on the Company, please visit our Web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th Mar 20197:00 amRNSCancellation of AIM Listing
25th Mar 20194:40 pmRNSSecond Price Monitoring Extn
25th Mar 20194:35 pmRNSPrice Monitoring Extension
20th Mar 201911:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Mar 201910:31 amRNSForm 8.5 (EPT/RI) Earthport Plc
18th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
15th Mar 20192:35 pmRNSResult of General Meeting
15th Mar 201910:09 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
14th Mar 201911:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Mar 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Mar 201911:53 amRNSForm 8.3 - Realm Therapeutics PLC
12th Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Mar 201910:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
8th Mar 201911:30 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Mar 201911:16 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Mar 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Mar 20199:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Mar 201911:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
1st Mar 201910:07 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Feb 201911:14 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Feb 20194:58 pmRNSForm 8.3 - Realm Therapeutics
27th Feb 20194:41 pmRNSSecond Price Monitoring Extn
27th Feb 20194:36 pmRNSPrice Monitoring Extension
27th Feb 201911:01 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
26th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Feb 201910:08 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
22nd Feb 201911:36 amGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics PLC
22nd Feb 201910:02 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Feb 20194:34 pmRNSForm 8.3 - Realm Therapeutics plc
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 20194:26 pmRNSHolding(s) in Company
21st Feb 201912:36 pmGNWInvesco Ltd.: Form 8.3 - Realm Therapeutics Plc
21st Feb 20199:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Feb 201910:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Feb 20192:05 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
19th Feb 20199:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Feb 20199:25 amRNSForm 8.5 (EPT/RI)Realm Therapeutics
18th Feb 20199:05 amRNSSecond Price Monitoring Extn
18th Feb 20199:00 amRNSPrice Monitoring Extension
18th Feb 20197:00 amRNSBlock listing Interim Review
18th Feb 20197:00 amRNSUpdate on Strategic Review Re-release
15th Feb 20196:20 pmRNSUpdate on Strategic Review
15th Feb 20199:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
11th Feb 201910:01 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Feb 20199:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Feb 201910:48 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Feb 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Feb 201911:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.